ViaCyte to Present at Two San Diego Events: Biocom’s Global Life Science Partnering Conference and UCSD Diabetes Public Forum


SAN DIEGO, February 23, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced two presentations by Dr. Paul Laikind, President and Chief Executive Officer.  Details are as follows:

Event:  UCSD Diabetes Public Forum hosted by the UCSD Pediatric Diabetes Research Center and the UCSD Sanford Stem Cell Clinical Center
Location:  Lobby, Sanford Consortium for Regenerative Medicine, La Jolla, Calif.
Presentation: Monday, February 23rd, from 5:30 p.m. to 7:30 p.m. PST

Event:  Biocom’s Global Life Science Partnering Conference
Location:  The Lodge at Torrey Pines, La Jolla, Calif.
Presentation:  Wednesday, February 25th, at 11:20 a.m. PST

Dr. Laikind will review recent progress with the company’s VC-01™ product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development.  A Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was launched in September 2014, and the first patient was successfully implanted at UC San Diego Health System in October 2014.

For more information about the events, please visit:

About ViaCyte

ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s VC-01 lead product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte’s VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

Investor Contact: Lisa Wilson, In-Site Communications, Inc., +1.212.452.2793,

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., +1.858.344.8091,